Navigating the AI Landscape in Healthcare: Ethics and Access

By Sumona Bose

December 11, 2023

Navigating the AI Landscape in Healthcare

The AI Challenge in Healthcare

The integration of Artificial Intelligence (AI) into the healthcare sector is a complex endeavour. Life sciences consulting firms are grappling with significant challenges, particularly when it comes to embedding AI-enabled diagnostics into healthcare systems. These challenges are rooted in sociocultural, technological, and institutional subsystems. The medical community’s prevailing ethos, concerns about black-box decision-making, and fear of reputational harm are some of the factors contributing to resistance against AI.

The Response: Stealth Science, Agility, and Digital Ambidexterity

AI providers are responding to these challenges with three key practices: stealth science, agility, and digital ambidexterity. Stealth science involves maintaining opacity around development to safeguard trade secrets and evade regulatory scrutiny. Agility refers to the capacity to adapt to different technical settings and learn from various healthcare environments. Lastly, digital ambidexterity is the pursuit of efficiency and innovation in developing AI technologies.

However, these practices may lead to complexities in technology spread, regulatory challenges, and shifts in healthcare dynamics. It’s clear that the journey towards integrating AI into healthcare is filled with paradoxes, with AI providers having to tread a fine line between acceleration and inertia.

The Ethical Considerations

From policy makers, ethics in access to AI is an important factor to consider. AI providers need to ensure that their practices allow for more latitude in navigating healthcare systems, but this must be balanced against the need for transparency and accountability.

To ensure value-based healthcare, we must address these ethical dilemmas head-on and work towards finding workable solutions. AI consulting firms must work in tandem with healthcare providers and policy-makers to create human-centred solutions that respect the rights and needs of all stakeholders.

Reference url

Recent Posts

regulatory validation taletrectinib
Advancing Regulatory Validation Taletrectinib for Enhanced NSCLC Treatment

By João L. Carapinha

June 30, 2026

The MHRA’s validation of Nuvation Bio’s marketing authorisation application marks an important regulatory validation taletrectinib for adults with advanced ROS1-positive non-small cell lung cancer. This milestone, achieved via the International Recognition Procedure in parallel with EMA review, f...
Portuguese Biotech Innovation
Global Impact of Portuguese Biotech Innovation

By João L. Carapinha

June 30, 2026

Portuguese Biotech Innovation has matured into a compelling global force, with Solfarcos marking a decade of translating University of Minho research into commercial technologies that span cosmetics and pharmaceuticals. The Braga-based spin-off has built a unified platform of peptides and protein...
cannabis regulatory exploitation
Exposing Cannabis Regulatory Exploitation in Portugal’s Medicinal Sector

By João L. Carapinha

June 30, 2026

Portugal’s medicines regulator INFARMED has been shaken by a major case of cannabis regulatory exploitation in which criminal networks weaponised medicinal cannabis licences to traffic drugs on an industrial scale. Insufficient inspectors, rapid sector growth and the recruitment of former agency ...